Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Sponsor
Armando Santoro, MD
Study ID
NCT01884441
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bendamustine — DRUG
    Schedule: Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles
  • Gemcitabine — DRUG
    Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
  • Vinorelbine — DRUG
    Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles

Study Details

Test of bendamustine in combination with gemcitabine and vinorelbine could contribute to a higher response rate with the reduction of toxic side effects

Key Dates

Start date
Jul 31, 2011
Status verified
Jan 2014
Primary completion
Jul 31, 2014
Completion
Jul 31, 2016

Study Design

Enrollment
59 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BeGEV
    Bendamustine, Gemcitabine and Vinorelbine (BeGEV)

Primary Outcome Measure

Response Rate [ Time Frame: 3 months ]

Central Contacts

Related Studies